Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma

Rougier, Philippe; Zarba, J. J.; Ducreux, Michel; Basile, Maria Luisa; Pignon, Jean-Pierre; Mahjoubi, M.; Benahmed, Mohamed; Droz, Jean‐Pierre; Cvitkovic, Esteban; Armand, Jean‐Pierre

doi:10.1093/oxfordjournals.annonc.a058495

Cited by 59 publications

(25 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…Cisplatin combined with 5-FU appears to be promising in metastatic pancreatic carcinoma, with a 26% response rate and a median survival rate of 7 months in a phase II trial (10). In a randomized trial comparing 5-FU with 5-FU plus cisplatin, FU-cisplatin was found to be superior to FU in terms of response and PFS, but not OS (9,10). The combination of S-1 and cisplatin has also been adopted in advanced gastric cancer, based on previous studies which revealed that combination therapy with S-1 and cisplatin had promising effects with tolerable toxicity (25,26).…”

Section: Discussionmentioning

confidence: 99%

“…The superior effect of combination therapy with cisplatin compared with 5-fluorouracil (5-FU) monotherapy has been Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients demonstrated in advanced pancreatic cancer (9,10). Thus, we conducted the present phase II study to investigate the feasibility and efficacy of S-1 in combination with cisplatin as palliative chemotherapy for gemcitabine-refractory advanced pancreatic cancer patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients

et al. 2012

View full text Add to dashboard Cite

Abstract. In this study, we examined the efficacy and toxicity of S-1 with cisplatin as a second-line palliative chemotherapy for gemcitabine-refractory pancreatic cancer patients. Patients who had been previously treated with gemcitabine-based chemotherapy as palliative first-line chemotherapy received S-1/cisplatin [body surface area (BSA) <1.25 m 2 , S-1 40 mg/ day; BSA ≤1.25 to <1.5 m 2 , 50 mg/day; BSA ≥1.5 m 2 60 mg/ day, orally, bid, daily on days 1-14 followed by a 7-day washout and cisplatin 60 mg/m 2 /day intravenously on day 1] every three weeks. The enrollment of 32 patients was planned, but the study was terminated early, prior to the first stage, following the enrollment of 11 patients. The median age of the patients was 56 (range, 42-74) years. Nine patients had a performance status (PS) of one. In total, there were 21 chemotherapy cycles and the median treatment duration was 21 (range, 7-96) days. Of the 11 patients, five could not be evaluated due to discontinuation prior to the response evaluation. One of the six evaluable patients achieved stable disease (9.1% in intention to treat analysis and 16.7% in per-protocol analysis), while five had progressive disease. Grade 3-4 hematological toxicities were anemia in one, neutropenia in one and thrombocytopenia in one cycle. Grade 3-4 nonhematological toxicities were fatigue in three, nausea in four, anorexia in two, diarrhea in one and peripheral neuropathy in two cycles. With a median follow-up period of 8.9 (range, 3.2-11.3) months, the median time to progression was 44 days [95% confidence interval (CI) 25.4-62.6] and the median overall survival was 81 days (95% CI 9.3-152.7). Combination chemotherapy with S-1 and cisplatin as applied in this study did not result in promising antitumor activity, a high degree of toxicity and poor compliance.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In these small trials, prolonged (at least 24 hours) infusion 5-FU was associated with better response and survival outcomes than bolus 5-FU, again suggesting that 5-FU activity in pancreatic cancer is schedule dependent. Grade 3/4 toxicities included neutropenia (12%-23%), nausea and vomiting (12%-17%), and mucositis (up to 14%) [92][93][94][95][96][97]. Combinations of platinum compounds with gemcitabine also have demonstrated encouraging outcomes with response rates ranging from 11%-31% and median survival times of 6-8.5 months (Table 2).…”

Section: Cisplatin and Oxaliplatinmentioning

confidence: 99%

Metastatic Pancreatic Cancer: Emerging Strategies in Chemotherapy and Palliative Care

2003

View full text Add to dashboard Cite

For these reasons, efforts at identifying and treating disease-related symptomatology are priorities. This update overviews symptom management, supportive care strategies, and both standard and emerging palliative chemotherapy options. The incorporation of molecularly targeted therapies into treatment of metastatic pancreatic cancer is reviewed as well. These strategies are of relevance to internists, gastroenterologists, oncologists, and other specialists who care for patients with pancreatic cancer.

show abstract

“…Although the clinical investigation of several antitumour agents has been conducted with a principal focus on fluorouracil, no agent has been found to suppress tumour growth. Also, there is no obvious improvement in the results of treatment with multiple drug therapy (Kelsen et al, 1991;Topham et al, 1991;Rougier et al, 1993;Nose et al, 1999) or the biochemical modulation of fluorouracil (Pazdur et al, 1992;Louvet et al, 1993;Weinerman and MacCormick, 1994;Bernhard et al, 1995). Gemcitabine, a nucleoside analogue, is efficacious in relieving the symptoms such as algia or general state in the case of nonscaling down of tumours (Casper et al, 1994).…”

mentioning

confidence: 99%

Antitumour effect of polyoxomolybdates: induction of apoptotic cell death and autophagy in in vitro and in vivo models

et al. 2007

View full text Add to dashboard Cite

O. The effect of PM-17 on the growth of cancer cell lines and xenografts was assessed by a cell viability test and analysis of tumour expansion rate. Morphological analysis was carried out by Hoechst staining, flow-cytometric analysis of Annexin V staining, terminal deoxynucleotidyl transferase-mediated 'nick-end' labelling staining, and electron-microscopic analysis. Activation of autophagy was detected by western blotting and fluorescence-microscopic analysis of the localisation of GFP-LC3 in transfected tumour cells. PM-17 inhibited the growth of human pancreatic cancer (AsPC-1) xenografts in a nude mice model, and induced morphological alterations in tumour cells. Correspondingly, PM-17 repressed the proliferation of AsPC-1 cells and human gastric cancer cells (MKN45) depending on the dose in vitro. We observed apoptotic patterns as the formation of apoptotic small bodies and translocation of phosphatidylserine by Hoechst staining and flow-cytometric analysis following Annexin V staining, and in parallel, autophagic conformation by the formulation of autophagosomes and localisation of GFP-LC3 by electron-and fluorescence-microscopic analysis.

show abstract

Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma

Abstract: The combination of CDDP and 5-FU in continuous infusion seems an active and well tolerated treatment in APC and will be compared to standard therapy in a multicentric randomized trial.

Cited by 59 publications

References 9 publications

Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients

Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients

Metastatic Pancreatic Cancer: Emerging Strategies in Chemotherapy and Palliative Care

Antitumour effect of polyoxomolybdates: induction of apoptotic cell death and autophagy in in vitro and in vivo models

Contact Info

Product

Resources

About